US2024034781A1PendingUtilityA1

Human antibody specific for interleukin-1alpha

90
Assignee: JANSSEN BIOTECH INCPriority: May 30, 2008Filed: Oct 9, 2023Published: Feb 1, 2024
Est. expiryMay 30, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:John Simard
C12N 5/10C07K 16/245C12N 5/069C12N 5/0693G01N 33/6869C07K 14/545G01N 33/6863C07K 14/5412G01N 2333/545A61K 2039/55527C07K 2317/21C07K 2317/76C07K 2317/92A61K 39/3955A61P 29/00A61P 35/00A61P 37/00A61P 37/06A61P 43/00A61P 9/10C12N 2330/50C07K 2317/14C07K 16/24A61K 39/395A61K 2039/505C07K 2317/24
90
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Claims

exact text as granted — not AI-modified
1 . A purified human IgG1 mAb that specifically binds to human IL-1α, the mAb comprising a heavy chain covalently joined to a light chain. 
     
     
         1 - 22 . (canceled) 
     
     
         23 . An IL-1α specific monoclonal antibody comprising (i) a heavy chain variable region having amino acid residues 20-141 of SEQ ID NO: 9 and a light chain variable region having amino acid residues 23-130 of SEQ ID NO: 11 and (ii) a constant region of a human IgG1 monoclonal antibody. 
     
     
         24 . A set of isolated nucleic acids encoding the monoclonal antibody of  claim 23 . 
     
     
         25 . A vector comprising the set of nucleic acids of  claim 24 . 
     
     
         26 . A host cell comprising the vector of  claim 25 .

Join the waitlist — get patent alerts

Track US2024034781A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.